Trial · NCT06274528
DORA and LP in Alzheimer's Disease Biomarkers
NCT06274528, Phase 2, Recruiting, University of Minnesota
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. DORA and LP in Alzheimer's Disease Biomarkers. Trials, record NCT06274528. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06274528
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- DORA and LP in Alzheimer's Disease Biomarkers
- NCT number
- NCT06274528
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 201 participants, estimated
- Lead sponsor
- University of Minnesota
- Conditions
- Alzheimer Disease
- Interventions
- Lemborexant 10 mg, Lemborexant 20mg, Placebo
- First posted
- 2024-02-23
- Last updated
- 2026-07-13
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes plasma pT181/T181 ratio of lemborexant 10 and 20 mg compared to Placebo | 6 months | plasma collection |
| Secondary | Number of participants with treatment-related adverse events | 6 months | Adverse events |
| Secondary | Measure the blood concentration of lemborexant 10 mg and 20 mg and determine the dose-response relationship with CSF pT181/T181 | 6 months | Blood collection |
| Secondary | Measure changes on blood plasma amyloid-beta isoforms (Aβ38, Aβ40, Aβ42, Aβ42/Aβ40) | 6 months | Blood collection |
| Secondary | Measure changes of CSF amyloid beta isoforms (Aβ38, Aβ40, Aβ42,Aβ42/Aβ40 ) | 6 months | CSF collection |
| Secondary | Measure changes of blood plasma p-tau/tau forms (T181, pT181, pT181/T181, S202, pS202, pS202/S202, T217, pT217, pT217/T217). | 6 months | Blood collection |
| Secondary | Measure changes of cerebrospinal fluid p-tau/tau forms (T181, pT181, S202, pS202, pS202/S202, T217, pT217, pT217/T217). | 6 months | CSF collection |
| Other | Measure changes of cerebrospinal TREM2 (exploratory) | 6 months | CSF |
| Other | Measure changes of cerebrospinal NPTX2 (exploratory) | 6 months | CSF |
| Other | Measure changes of cerebrospinal NfL (exploratory) | 6 months | CSF |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01AG080551 | Effect of Suvorexant on Alzheimer's Disease Biomarkers | LUCEY, BRENDAN PATRICK | WASHINGTON UNIVERSITY | NATIONAL INSTITUTE ON AGING | 2023 to 2024 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06274528
GET https://conductscience.org/api/trials/v1/NCT06274528/registered